No new items were published in the sources we monitor on this date. The open consultations and hearings below remain current.
Federal Official Gazette
No updates.
ANS news
No updates.
Open public consultations
- CP 163. Its purpose is to receive input on the proposed updates to the List of Health Procedures and Events (Rol), specifically on the preliminary recommendation of non-incorporation for the technologies covered by UAT No. 171 – Inclisiran, UAT No. 175 – Lebrikizumab and UAT No. 176 – Momelotinib. Deadline: Nov 5, 2025 to Nov 24, 2025
Scheduled public hearings
- Public Hearing No. 61, collection of input on the preliminary recommendation of non-incorporation for the following technologies:
(i) UAT 171 – Inclisiran for the treatment of primary hypercholesterolemia or mixed dyslipidemia;
(ii) UAT 175 – Lebrikizumab for the treatment of adult patients with severe atopic dermatitis who have failed, are intolerant to or have a contraindication to cyclosporine; and
(iii) UAT 176 – Momelotinib for the treatment of intermediate- and high-risk myelofibrosis.
Date: November 19, 2025, from 9 a.m. to 1 p.m.
Open public calls for input
There are no open public calls for input.
Open public calls
No updates.
Other news
– No updates.
Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.